XML 26 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure [Table]      
Pay vs Performance [Table Text Block]
Pay Versus Performance Table
 
                                
Value of Initial Fixed $100
Investment Based on:
     
(in thousands)
  
  Year
   
Summary
Compensation
Table Total for
PEO ($)(1)
     
Compensation
Actually Paid to
PEO ($) (1)(3)(5)
     
Average Summary
Compensation
Table Total for
non-PEO
NEOs ($)
(2)
     
Average
Compensation
Actually Paid to
non-PEO NEOs

($)(2)(4)(5)
     
TSR ($) (6)
     
Peer Group
TSR ($) (6)
     
Net Loss ($)
    
Company
Selected
Measure
(CSM) - 
Net

Product
Revenue ($)
  
  2022
      4,588,810        30,375,480        3,580,510        17,466,190        206.35        113.65        (1,131,156 )      894,329  
  2021
      10,176,685        17,514,345        5,918,910        10,714,290        147.24        126.45        (852,824 )      662,138  
  2020
      7,818,164        17,306,949        4,240,550        6,617,560        112.85        126.42        (858,281 )      361,520  
 
  (1)
For 2022, our PEO was Yvonne L. Greenstreet, MBChB, MBA. For 2021 and 2020, our PEO was John M. Maraganore, Ph.D.
 
  (2)
For 2022, our
non-PEO
NEOs were
Akshay K. Vaishnaw, Jeffrey V. Poulton, Pushkal P. Garg, M.D., and Indrani L. Franchini, J.D. 
For 2021, our
non-PEO
NEOs were Dr. Greenstreet, Dr. Vaishnaw, Mr. Poulton, and Mr. Tanguler. For 2020, our
non-PEO
NEOs were Dr. Greenstreet, Dr. Vaishnaw, Mr. Poulton, Laurie B. Keating, and Barry E. Greene.
 
  (3)
Following is a summary of the adjustments made to PEO compensation as reported in the Summary Compensation Table to determine PEO CAP as reported in this table:
 
    
2022
    
2021
    
2020
  
Total Compensation Reported in SCT
      4,588,810       10,176,685       7,818,164  
LESS: the grant date fair value of equity awards granted in the year indicated
      (2,498,790 )      (7,861,410 )      (5,746,295 ) 
ADD: the
year-end
fair value of outstanding and unvested equity awards granted in the year indicated (a)
      18,073,160       9,100,080       14,001,000  
ADD: the change in fair value of equity awards granted years prior to the year indicated that were outstanding and unvested at the end of the year indicated (as compared to fair value at the end of the immediately prior year) (a)
      6,436,300       2,419,780       953,260  
ADD: the change in fair value of equity awards granted years prior to the year indicated that vested in the year indicated (fair value at vesting date as compared to the end of the immediately prior year) (a)
      3,776,000       3,679,210       280,820  
Total (Net) Adjustments
      30,375,480       17,514,345       17,306,949  
 
  (a)
We determined the
year-end
fair value of PSUs for the year indicated, if the achievement of the performance condition for the PSU was not probable, as defined under applicable accounting guidance, then we assigned a fair value of $0.
 
  (4)
Following is a summary of the adjustments made to average
non-PEO
NEO compensation as reported in the Summary Compensation Table to determine average
non-PEO
NEO CAP as reported in this table:
 
    
2022
    
2021
    
2020
  
Average Total Compensation Reported in SCT
      3,580,510       5,918,910       4,240,550  
LESS: the grant date fair value of equity awards granted in the year indicated
      (2,548,800 )      (4,891,560 )      (3,113,250 ) 
ADD: the
year-end
fair value of outstanding and unvested equity awards granted in the year indicated (a)
      11,045,880       6,583,990       4,670,300  
ADD: the change in fair value of equity awards granted years prior to the year indicated that were outstanding and unvested at the end of the year indicated (as compared to fair value at the end of the immediately prior year) (a)
      3,343,110       962,260       450,100  
ADD: the change in fair value of equity awards granted years prior to the year indicated that vested in the year indicated (fair value at vesting date as compared to the end of the immediately prior year) (a)
      2,045,490       2,140,690       369,860  
Total (Net) Adjustments
      17,466,190       10,714,290       6,617,560  
 
  (a)
We determined the
year-end
fair value of PSUs for the year indicated, if the achievement of the performance condition for the PSU was not probable, as defined under applicable accounting guidance, then we assigned a fair value of $0.
 
  (5)
In calculating CAP reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations were computed in accordance with FASB ASC Topic 718. We did not report a change in pension benefit values for any of the years reflected in the table, and therefore adjustments to pension benefit values were not included in calculating CAP reflected in these columns, because we do not sponsor, maintain or contribute to a defined benefit pension plan.
 
  (6)
The Company TSR and the Company’s Peer Group TSR reflected in these columns for each applicable fiscal year is calculated based on a fixed investment of $100 at the applicable measurement point on the same cumulative basis as is used in Item 201(e) of Regulation
S-K.
The peer group used to determine the Company’s Peer Group TSR for each applicable fiscal year is the following published industry index, as disclosed in our Annual Report on Form
10-K
for the year ended December 31, 2022 pursuant to Item 201(e) of Regulation
S-K:
Nasdaq Biotechnology
Total Return
Index (
X
NBI).
   
Company Selected Measure Name NetProductRevenue    
Named Executive Officers, Footnote [Text Block] Akshay K. Vaishnaw, Jeffrey V. Poulton, Pushkal P. Garg, M.D., and Indrani L. Franchini, J.D. Dr. Greenstreet, Dr. Vaishnaw, Mr. Poulton, and Mr. Tanguler. Dr. Greenstreet, Dr. Vaishnaw, Mr. Poulton, Laurie B. Keating, and Barry E. Greene.
Peer Group Issuers, Footnote [Text Block] The Company TSR and the Company’s Peer Group TSR reflected in these columns for each applicable fiscal year is calculated based on a fixed investment of $100 at the applicable measurement point on the same cumulative basis as is used in Item 201(e) of Regulation
S-K.
The peer group used to determine the Company’s Peer Group TSR for each applicable fiscal year is the following published industry index, as disclosed in our Annual Report on Form
10-K
for the year ended December 31, 2022 pursuant to Item 201(e) of Regulation
S-K:
Nasdaq Biotechnology
Total Return
Index (
X
NBI). 		   
PEO Total Compensation Amount $ 4,588,810 $ 10,176,685 $ 7,818,164
PEO Actually Paid Compensation Amount $ 30,375,480 17,514,345 17,306,949
Adjustment To PEO Compensation, Footnote [Text Block]
  (3)
Following is a summary of the adjustments made to PEO compensation as reported in the Summary Compensation Table to determine PEO CAP as reported in this table:
 
    
2022
    
2021
    
2020
  
Total Compensation Reported in SCT
      4,588,810       10,176,685       7,818,164  
LESS: the grant date fair value of equity awards granted in the year indicated
      (2,498,790 )      (7,861,410 )      (5,746,295 ) 
ADD: the
year-end
fair value of outstanding and unvested equity awards granted in the year indicated (a)
      18,073,160       9,100,080       14,001,000  
ADD: the change in fair value of equity awards granted years prior to the year indicated that were outstanding and unvested at the end of the year indicated (as compared to fair value at the end of the immediately prior year) (a)
      6,436,300       2,419,780       953,260  
ADD: the change in fair value of equity awards granted years prior to the year indicated that vested in the year indicated (fair value at vesting date as compared to the end of the immediately prior year) (a)
      3,776,000       3,679,210       280,820  
Total (Net) Adjustments
      30,375,480       17,514,345       17,306,949  
 
  (a)
We determined the
year-end
fair value of PSUs for the year indicated, if the achievement of the performance condition for the PSU was not probable, as defined under applicable accounting guidance, then we assigned a fair value of $0.
   
Non-PEO NEO Average Total Compensation Amount $ 3,580,510 5,918,910 4,240,550
Non-PEO NEO Average Compensation Actually Paid Amount $ 17,466,190 10,714,290 6,617,560
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
  (4)
Following is a summary of the adjustments made to average
non-PEO
NEO compensation as reported in the Summary Compensation Table to determine average
non-PEO
NEO CAP as reported in this table:
 
    
2022
    
2021
    
2020
  
Average Total Compensation Reported in SCT
      3,580,510       5,918,910       4,240,550  
LESS: the grant date fair value of equity awards granted in the year indicated
      (2,548,800 )      (4,891,560 )      (3,113,250 ) 
ADD: the
year-end
fair value of outstanding and unvested equity awards granted in the year indicated (a)
      11,045,880       6,583,990       4,670,300  
ADD: the change in fair value of equity awards granted years prior to the year indicated that were outstanding and unvested at the end of the year indicated (as compared to fair value at the end of the immediately prior year) (a)
      3,343,110       962,260       450,100  
ADD: the change in fair value of equity awards granted years prior to the year indicated that vested in the year indicated (fair value at vesting date as compared to the end of the immediately prior year) (a)
      2,045,490       2,140,690       369,860  
Total (Net) Adjustments
      17,466,190       10,714,290       6,617,560  
 
  (a)
We determined the
year-end
fair value of PSUs for the year indicated, if the achievement of the performance condition for the PSU was not probable, as defined under applicable accounting guidance, then we assigned a fair value of $0.
   
Compensation Actually Paid vs. Total Shareholder Return [Text Block]    
Compensation Actually Paid vs. Net Income [Text Block]    
Compensation Actually Paid vs. Company Selected Measure [Text Block]    
Total Shareholder Return Vs Peer Group [Text Block]    
Total Shareholder Return Amount $ 206.35 147.24 112.85
Peer Group Total Shareholder Return Amount 113.65 126.45 126.42
Net Income (Loss) $ (1,131,156,000) $ (852,824,000) $ (858,281,000)
Company Selected Measure Amount 894,329,000 662,138,000 361,520,000
PEO Name Yvonne L. Greenstreet John M. Maraganore John M. Maraganore
PEO [Member] | the grant date fair value of equity awards granted in the year indicated [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ (2,498,790) $ (7,861,410) $ (5,746,295)
PEO [Member] | the yearend fair value of outstanding and unvested equity awards granted in the year indicated (a) [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 18,073,160 9,100,080 14,001,000
PEO [Member] | the change in fair value of equity awards granted years prior to the year indicated that were outstanding and unvested at the end of the year indicated (as compared to fair value at the end of the immediately prior year) (a) [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 6,436,300 2,419,780 953,260
PEO [Member] | the change in fair value of equity awards granted years prior to the year indicated that vested in the year indicated (fair value at vesting date as compared to the end of the immediately prior year) (a) [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 3,776,000 3,679,210 280,820
Non-PEO NEO [Member] | the grant date fair value of equity awards granted in the year indicated [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (2,548,800) (4,891,560) (3,113,250)
Non-PEO NEO [Member] | the yearend fair value of outstanding and unvested equity awards granted in the year indicated (a) [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 11,045,880 6,583,990 4,670,300
Non-PEO NEO [Member] | the change in fair value of equity awards granted years prior to the year indicated that were outstanding and unvested at the end of the year indicated (as compared to fair value at the end of the immediately prior year) (a) [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 3,343,110 962,260 450,100
Non-PEO NEO [Member] | the change in fair value of equity awards granted years prior to the year indicated that vested in the year indicated (fair value at vesting date as compared to the end of the immediately prior year) (a) [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ 2,045,490 $ 2,140,690 $ 369,860